Glossary · Clinical

Joint (intra-articular) injection

A joint (intra-articular) injection delivers medication—such as a corticosteroid, hyaluronic acid, or anesthetic—directly into a joint space to relieve pain, reduce inflammation, or restore lubrication. The procedure is coded using CPT arthrocentesis codes 20600–20611, selected by joint size and whether ultrasound guidance is used.

Verified May 8, 2026 · 6 sources ↓

Drawn from CMSAAPCCmadocsThe-rheumatologist

Definition

Source · Editorial summary grounded in 6 cited references ↓

An intra-articular injection places a therapeutic agent inside the synovial cavity of a joint. Common injectates include corticosteroids (to reduce acute inflammation), hyaluronic acid derivatives (viscosupplementation for osteoarthritis), platelet-rich plasma, and local anesthetics. The same needle access may be used to aspirate synovial fluid before or after injection, and both actions are captured under a single arthrocentesis code for that joint encounter.

CPT code selection depends on two variables: joint size and imaging guidance. Small joints (fingers, toes) use 20600 (no guidance) or 20604 (ultrasound guidance). Intermediate joints—wrist, elbow, ankle, temporomandibular, acromioclavicular—use 20605 or 20606. Major joints (shoulder, hip, knee, subacromial bursa) use 20610 or 20611. When fluoroscopic, CT, or MRI guidance is used instead of ultrasound, those imaging services may be reported separately. Ultrasound guidance is bundled into the -04/-06/-11 variants and cannot also be billed separately.

For hyaluronic acid injections billed to Medicare, an HCPCS Level II drug code (e.g., J7321–J7332, J7323) must accompany the injection procedure code to capture the drug supply. A series of injections requires the EJ modifier on the drug code for each injection after the first. Coverage criteria, injection frequency limits, and required diagnosis codes vary by Medicare Administrative Contractor (MAC) local coverage determination (LCD).

Why it matters

Selecting the wrong CPT code—most often 20610 when ultrasound guidance was actually used (correct code: 20611), or reporting imaging guidance as a separate line item when it is already bundled—triggers NCCI edits, automated denials, and potential overpayment recoupment on audit. Conversely, failing to separately bill the drug HCPCS code on Medicare claims means the practice absorbs the drug cost entirely. For bilateral injections, omitting the modifier 50 (or RT/LT modifiers as CMS requires) routinely causes one of two claim lines to deny, directly reducing reimbursement on high-volume injection days.

Common mistakes

Where people most often go wrong with this concept.

Source · Editorial brief grounded in cited references ↓

Billing 20610 when ultrasound guidance was documented and performed—20611 is required, and the guidance is not separately reportable.
Reporting fluoroscopic or CT guidance as a separately billed code when it was not actually used—imaging guidance is only separately reportable for fluoroscopy, CT, or MRI, not for ultrasound.
Billing multiple units of 20610 for two injections in the same joint (e.g., medial and lateral knee)—only one unit per joint per encounter is correct.
Failing to append RT or LT modifier on 20610/20611 for knee injections as required by CMS billing instructions.
Billing bilateral injections of the same joint (e.g., both knees) as two separate line items without modifier 50, or using 50 instead of separate RT/LT line items per payer-specific rules.
Reporting the injection procedure code on subsequent hyaluronic acid visits without appending the EJ modifier to the drug HCPCS code, causing the payer to treat each as a first-in-series injection.
Reporting a same-day E/M service with a planned injection visit when no separately identifiable problem was addressed—this is a common audit target requiring modifier 25 only when a distinct E/M is genuinely warranted.
Linking the drug HCPCS code to an unspecified osteoarthritis ICD-10 code (e.g., M17.9) instead of the laterality-specific code (e.g., M17.11 or M17.12) required by many MACs for hyaluronic acid coverage.

Related codes

Codes commonly involved when this concept appears in practice.

CPT

ICD-10

M17.11 M17.12 M17.31 M17.32

Modifiers

50 Bilateral procedure LT Left side RT Right side 25 Significant separately identifiable E/M 59 Distinct procedural service

Frequently asked questions

Source · Generated from the editorial pipeline, verified against 6 cited references ↓

01Can I bill both an aspiration and an injection of the same joint at the same visit?

Yes, but only as a single unit of the appropriate arthrocentesis code (20600, 20605, or 20610). Both the aspiration and the injection are bundled into one code per joint per encounter—billing two units is incorrect and will trigger NCCI edits.

02When is ultrasound guidance separately billable for a joint injection?

Never—when ultrasound is used, select the guidance-inclusive code (20604, 20606, or 20611). Ultrasound guidance is bundled into those codes. Only fluoroscopic, CT, or MRI guidance may be reported as a separate add-on service.

03How do I bill bilateral knee injections to Medicare?

CMS instructs providers to report 20610 with the RT modifier on one line and 20610 with the LT modifier on a second line. Append modifier 50 per non-Medicare payer instructions if that payer requires it instead. Check the individual payer's billing guidelines before defaulting to either method.

04Does the drug always need its own HCPCS code?

For Medicare and most Medicaid plans, yes—the injection CPT code covers the physician work, not the drug. Report the applicable HCPCS J-code (e.g., J7323 for Euflexxa, J7325 for Synvisc) separately with correct units. If the patient's commercial plan bundles the drug, verify that payer's policy before adding the J-code.

05What is the EJ modifier and when is it required?

The EJ modifier indicates a 'subsequent delivery for a current course of therapy.' For multi-injection hyaluronic acid series (e.g., three weekly Synvisc injections), append EJ to the drug HCPCS code on the second and third injection dates. Omitting it causes the payer to treat each visit as a first-in-series, which can trigger quantity-limit denials.

06Can I bill an E/M service on the same day as a planned joint injection?

Only if a separately identifiable problem beyond the planned injection was addressed and documented. Append modifier 25 to the E/M code. Routine pre-injection assessment (confirming the patient is ready for the scheduled injection) does not support a separate E/M service.

Sources & references

Editorial content was developed using the following public sources. Last verified May 8, 2026.

Mira AI Scribe

MIRA SCRIBE GUIDANCE — Joint (Intra-articular) Injection Capture these elements in the note to support accurate code selection and reduce denial risk: 1. JOINT IDENTITY & LATERALITY: Name the specific joint and side (e.g., 'right knee,' 'left shoulder'). Unspecified laterality blocks RT/LT modifier assignment and can cause MAC denials on hyaluronic acid claims. 2. JOINT SIZE CATEGORY: The note must allow the coder to confirm small (fingers/toes), intermediate (wrist, elbow, ankle, TMJ, AC joint), or major (shoulder, hip, knee, subacromial bursa) to drive code selection between the 20600–20611 family. 3. GUIDANCE USED: Document whether ultrasound guidance was used, with a statement that permanent recording and reporting occurred. If ultrasound was used, 20611/20606/20604 applies and guidance is NOT separately billable. If fluoroscopy, CT, or MRI guided the injection, note that separately—those may be billed as add-on services. 4. INJECTATE: Specify the drug name, concentration, and dose administered (e.g., 'Synvisc-One 48 mg intra-articular'). For hyaluronic acid products, the exact product name determines the correct HCPCS J-code and unit count. 5. ASPIRATION: If fluid was aspirated before or after injection, document it. Both aspiration and injection of the same joint are captured under a single CPT unit—do not inflate to two codes. 6. SERIES POSITION: For multi-injection HA series, flag whether this is the first injection or a subsequent injection. Subsequent injections require the EJ modifier on the drug HCPCS code. 7. SAME-DAY E/M: If an E/M service is also being billed, document a separately identifiable clinical problem addressed beyond the planned injection to support modifier 25.

See Mira's approach

Viscosupplementation is the intra-articular injection of hyaluronic acid (HA) into the knee joint to restore the viscoelastic properties of synovial fluid that are diminished in osteoarthritis. It is FDA-approved for knee OA pain unresponsive to conservative non-pharmacologic therapy and simple analgesics.

Corticosteroid injection Clinical

A corticosteroid injection is an in-office procedure in which a steroid medication—such as triamcinolone acetonide or methylprednisolone acetate—is deposited directly into a joint, bursa, or soft-tissue structure to reduce inflammation and relieve pain. It is billed with a joint-specific CPT code (20600–20611) plus a separate HCPCS drug code for the agent administered.

Local Coverage Determination (LCD) Compliance

A Local Coverage Determination (LCD) is a regional Medicare policy issued by a Medicare Administrative Contractor (MAC) that defines when a specific service, procedure, or supply is considered reasonable and medically necessary within that contractor's jurisdiction.